Owner Investor / Financier Operator Developer Technology licensor Technology / equipment supplier
Mitsui Chemicals, Inc. is a Japan-based global chemical manufacturer that develops and produces petrochemicals, basic chemicals, and a wide range of performance and specialty materials. Its portfolio spans polyolefins, phenols and intermediates, elastomers, engineering plastics, functional films and adhesives, nonwovens, ophthalmic lens monomers, agricultural materials, and other fine chemicals used in industrial and consumer applications.
The company serves markets including automotive and mobility, electronics and ICT, packaging, healthcare and medical, consumer goods, and agriculture. Mitsui Chemicals operates R&D and manufacturing sites across Japan, Asia, Europe, and the Americas, supported by regional subsidiaries such as Mitsui Chemicals Europe and Mitsui Chemicals America. The group also participates in joint ventures in key product areas and pursues technology development aimed at material efficiency, circularity, and lower environmental impact.
Also known as Mitsui Chemicals Europe GmbH, Mitsui Chemicals Europe, Mitsui Chemicals Group, Mitsui Chemicals America Inc., MCI and 4 more.
chemXplore tracks 6 projects involving Mitsui Chemicals, of which 2 are active.
Besides these 2, the record holds 3 completed projects and 1 cancelled.
Closest to start-up first.
The 4 that are completed, on hold or cancelled are in the record. See all 6 in chemXplore
The company reported stronger results across most segments and outlined a ¥1.84 trillion agreement to acquire JSR, subject to regulatory approvals.
Executives discuss portfolio strategy, semiconductor growth, integration plans, financing and regulatory approvals.
Plans to buy JSR for ¥1.84 trillion, target closing in H2 of FY ending March 2028; DBJ to co-invest ¥200bn; shelf registration up to ¥150bn to help refinance a ¥1,640bn bridge loan.
Plans to build a global specialty semiconductor-materials platform, target operating income ≥¥300bn, EV ~¥1.392tn with ¥447.9bn debt assumed, DBJ to invest ¥200bn in preferred shares; closing H2 FY27.
Links Mitsui's materials and InnoCell plates with an AI-driven closed-loop platform to improve uniformity and manufacture of human cells and organoids for drug discovery and regenerative medicine.
Adherent culture plate with high oxygen permeability, enhanced surface treatment, low autofluorescence and low drug adsorption to improve organoid culture and screening.
New ammonia-fired burners enabled a world-class 85% heat-input co‑firing rate in a test naphtha cracking furnace while keeping NOx comparable to current furnaces.
100-Day Plan ties AI/DX, R&D and plant strategies to stretch targets: Team A ¥10bn new-business profit, Team D ¥10bn cost reduction, 10 R&D-led businesses, and DX profit contribution by 2030.
active all projects